Aralkyl diazabicycloalkane derivatives for CNS disorders

US5679679A · kind A · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Wayne Bowen · Derwood, US
• Brian R. de Costa · Rockville, US
• Celia Dominguez · Los Angeles, US
• Xiao He · Branford, US
• Kenner C. Rice · Bethesda, US

Key dates

• Filing date: Dec 2, 1994
• Grant date: Oct 21, 1997
• Expiry date: Dec 2, 2014

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Certain aralkyl diazabicyloalkyl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychoses and convulsions. Compounds of particular interest are of the formula: ##STR1## wherein: each of R.sup.1, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is independently selected from the group consisting of hydrido, loweralkyl, benzyl and haloloweralkyl; PA1 each of R.sup.2, R.sup.3, and R.sup.8 through R.sup.11 is independently selected from the group consisting of hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; PA1 n is an integer of from three to four; PA1 m is an integer of two; PA1 A is selected from the group consisting of phenyl, naphthyl, benzothienyl, benzofuranyl and thienyl and wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from the group consisting of hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; PA0 or a pharmaceutically acceptable salt thereof.